Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immunomedics, Inc. (NASDAQ: IMMU).

Full DD Report for IMMU

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMMU)

Immunomedics (IMMU) Presents At Baird's Global Healthcare Conference - Slideshow
The following slide deck was published by Immunomedics, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 14:51
Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Immunomedics: Why This Biotech Could Go Crazy In 2019
Clinical-stage biopharma Immunomedics (IMMU) is a heavyweight player soaring in the worldwide antibody-drug conjugate ((ADC)) market. In other words, the company specializes in cancer therapies, and it’s been a standout year for investors. Notably, IMMU’s lead investigational A...
Source: SeekingAlpha
Date: August, 29 2018 08:30
Today's Research Reports on Trending Tickers: Tetraphase Pharmaceuticals and Immunomedics
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with the U.S. and Mexico. The Dow Jones Industrial Average jumped 1.01 percent to close at 2...
Source: ACCESSWIRE IA
Date: August, 28 2018 08:00
Immunomedics Announces Participation in Upcoming Healthcare Conferences
MORRIS PLAINS, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Michael Pehl, President an...
Source: GlobeNewswire
Date: August, 28 2018 08:00
Powell To Center Stage In Jackson Hole (Wall Street Breakfast Podcast)
Editor's note: Seeking Alpha is proud to welcome WSB Podcast as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Today's top ...
Source: SeekingAlpha
Date: August, 24 2018 07:36
Immunomedics Q4 revenues down 33%
Immunomedics ( IMMU ) Q4 results : Revenues: $0.4M (-33.3%); Net Loss: ($117M) (-119.5%); Loss Per Share: ($0.68) (-41.7%); Quick Assets: $638.8M. More news on: Immunomedics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 24 2018 06:32
Wall Street Breakfast: Powell To Center Stage In Jackson Hole
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Federal Reserve Chairman Jerome Powell is due to give a speech about monetary policy in a changing economy at the ...
Source: SeekingAlpha
Date: August, 24 2018 06:15
Immunomedics, Inc. (IMMU) CEO Michael Pehl on Q4 2018 Results - Earnings Call Transcript
Immunomedics, Inc. (IMMU) Q4 2018 Earnings Conference Call August 23, 2018 5:00 PM ET Executives Chau Cheng - Senior Director, Investor Relations and Corporate Secretary Michael Pehl - President and Chief Executive Officer Brendan Delaney - Chief Commercial Officer Mike Garone ...
Source: SeekingAlpha
Date: August, 23 2018 20:34
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
Biologics License Application (BLA) Accepted for Filing and Granted Priority Review by the U.S. Food and Drug Administration (FDA) U.S. Commercial Launch Preparations on Track Lifecycle Management Strategy Implemented to Advance Sacituzumab Govitecan to Earlier Lines of Therapies a...
Source: GlobeNewswire
Date: August, 23 2018 16:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1418.8618.6219.4118.62849,473
2018-12-1319.6419.1819.9418.92903,172
2018-12-1218.9819.5219.8018.781,171,435
2018-12-1119.0818.9319.4818.59811,617
2018-12-1017.5719.0119.2117.401,487,933

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14149,067234,10563.6753Short
2018-12-13161,622262,31961.6128Short
2018-12-12133,359347,38638.3893Short
2018-12-11148,159292,56650.6412Short
2018-12-10188,150607,27630.9826Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMMU.


About Immunomedics, Inc. (NASDAQ: IMMU)

Logo for Immunomedics, Inc. (NASDAQ: IMMU)

Not available

 

Contact Information

 

 

Current Management

  • Cynthia L. Sullivan / President, CEO
  • Shailesh R. Asher / Acting CFO

Current Share Structure

  • Market Cap: $3,148,230,032 - 05/11/2018
  • Issue and Outstanding: 165,783,572 - 02/08/2018

 


Recent Filings from (NASDAQ: IMMU)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 02 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: IMMU)

Daily Technical Chart for (NASDAQ: IMMU)


Stay tuned for daily updates and more on (NASDAQ: IMMU)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IMMU)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMU is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMMU and does not buy, sell, or trade any shares of IMMU. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/